Dosimetry evaluation in 177Lu-labeled somatostatin receptor analogue therapy

#3819

Introduction: Dosimetry reporting in patients receiving PRRT is fundamental to ensure the safety and efficacy of treatment.

Aim(s): Develop a convenient and effective way to perform dosimetry evaluation in PRRT and to assess the feasibility of pre-treatment dosimetry, also simplify dosimetry approaches in common clinical practice.

Materials and methods: A 21 patients, mean age 58,6 years (range 32 – 77) all GEP-NET 14 pancreas (panNET) and 7 midgut NETG1/G2. PRRT using 177Lu-DOTATOC included 3-4 cycles with 2-month intervals. An average dose 6243 MBq of 177Lu in each case, all had post-therapy SPECT-CT. In 8 of patients also the pre-treatment diagnostic somatostatin receptor scintigraphy (SRS) with [99mTc]HYNIC-TOC. Dose calculations were carried out in OLINDA/EXM software. Also, doses for tracer accumulating lesions were calculated. Their masses were determined using quantitative analysis software for SPECT images provided by the scanner manufacturer (GE Dosimetry Toolkit).

Conference:

Presenting Author:

Authors: Cichoński A, Kempińska-Wróbel M, Kolasińska-Ćwikła A, Zrajkowska A, Szarowicz A,

Keywords: radionuclide therapy, dosimetry, lutetium,